General Information of Drug (ID: DMNTDFV)

Drug Name
6-Cl-IMP Drug Info
Synonyms
Hadacidin; N-FORMYL-N-HYDROXYGLYCINE; 689-13-4; Hadacidine; Asymmetrin; Hadacin; Nfhaa; N-Formyl hydroxyaminoacetic acid; UNII-BFO5P1010A; Glycine,N-formyl-N-hydroxy-; 2-(N-Hydroxyformamido)acetic acid; GLYCINE, N-FORMYL-N-HYDROXY-; NSC 72962; BRN 1927168; N-hydroxyformamidoacetic acid; CHEMBL331373; BFO5P1010A; CHEBI:43040; [formyl(hydroxy)amino]acetic acid; NSC 521778; N-formyl-N- hydroxyaminoacetic acid; hadicidine; SCHEMBL2115651; AC1L207A; DTXSID1043962; CTK5C8639; (Formyl-hydroxy-amino)-acetic acid; ZINC1482078
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
12717
ChEBI ID
CHEBI:43040
CAS Number
CAS 689-13-4
TTD Drug ID
DMNTDFV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [3]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [4]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [5]
Tiazofurin DM5JWV9 Solid tumour/cancer 2A00-2F9Z Approved [6]
Mizoribine DMW6F0S Transplant rejection NE84 Approved [5]
Viramidine DMJFNR9 Hepatitis C virus infection 1E51.1 Phase 3 [7]
VX-944 DME321B Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
VX-148 DML32R8 Psoriasis vulgaris EA90 Patented [9]
PMID28074661-Compound-US20100022547C81 DMM9E1U N. A. N. A. Patented [8]
PMID28074661-Compound-US20120264760C80 DM75QVW N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-Sulfhydryl-Ethanol DMJBO3D Discovery agent N.A. Investigative [10]
Guanosine-5'-Diphosphate DM0MUKQ Discovery agent N.A. Investigative [10]
Inosinic Acid DMLR86H Discovery agent N.A. Investigative [10]
Diphosphate DMHY30B Discovery agent N.A. Investigative [10]
(Carboxyhydroxyamino)Ethanoic Acid DMZB0C3 Discovery agent N.A. Investigative [10]
(C8-R)-Hydantocidin 5'-Phosphate DM5WH6R Discovery agent N.A. Investigative [10]
(C8-S)-Hydantocidin 5'-Phosphate DMMH179 Discovery agent N.A. Investigative [10]
6-O-Phosphoryl Inosine Monophosphate DM6YHBR Discovery agent N.A. Investigative [10]
Hydantocidin-5'-Monophosphate DMOTXP1 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) TTL7C8Q IMDH1_HUMAN Inhibitor [2]
Plasmodium Adenylosuccinate synthetase (Malaria Adss) TTYQ4AE PURA_PLAFA Inhibitor [1]

References

1 High performance liquid chromatography analysis of hypoxanthine metabolism in mouse oocyte-cumulus cell complexes: effects of purine metabolic perturbants. Biol Reprod. 1994 Jun;50(6):1403-12.
2 Identification of the IMP binding site in the IMP dehydrogenase from Tritrichomonas foetus. Biochemistry. 1995 Oct 24;34(42):13889-94.
3 Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67.
4 Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13.
5 VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
6 In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30.
7 Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
8 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
9 Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther. 2002 Sep;302(3):1272-7.
10 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.